NO20032101D0 - Apoliprotein analoger - Google Patents

Apoliprotein analoger

Info

Publication number
NO20032101D0
NO20032101D0 NO20032101A NO20032101A NO20032101D0 NO 20032101 D0 NO20032101 D0 NO 20032101D0 NO 20032101 A NO20032101 A NO 20032101A NO 20032101 A NO20032101 A NO 20032101A NO 20032101 D0 NO20032101 D0 NO 20032101D0
Authority
NO
Norway
Prior art keywords
apoliprotein
analogues
apoliprotein analogues
Prior art date
Application number
NO20032101A
Other languages
English (en)
Other versions
NO20032101L (no
NO331274B1 (no
Inventor
Jonas Graversen
Soeren Moestrup
Original Assignee
Proteopharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteopharma Aps filed Critical Proteopharma Aps
Publication of NO20032101D0 publication Critical patent/NO20032101D0/no
Publication of NO20032101L publication Critical patent/NO20032101L/no
Publication of NO331274B1 publication Critical patent/NO331274B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20032101A 2000-11-10 2003-05-09 Apolipoproteinanaloger NO331274B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200001682 2000-11-10
DKPA200100057 2001-01-15
US26402201P 2001-01-26 2001-01-26
PCT/DK2001/000739 WO2002038609A2 (en) 2000-11-10 2001-11-09 Apolipoprotein conjugates

Publications (3)

Publication Number Publication Date
NO20032101D0 true NO20032101D0 (no) 2003-05-09
NO20032101L NO20032101L (no) 2003-07-08
NO331274B1 NO331274B1 (no) 2011-11-14

Family

ID=27222453

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032101A NO331274B1 (no) 2000-11-10 2003-05-09 Apolipoproteinanaloger

Country Status (10)

Country Link
US (4) US6897039B2 (no)
EP (2) EP2343317A1 (no)
JP (2) JP4344136B2 (no)
CN (1) CN1268641C (no)
AU (2) AU2002213843B2 (no)
BR (1) BR0115257A (no)
CA (1) CA2428114C (no)
CY (1) CY1111118T1 (no)
NO (1) NO331274B1 (no)
WO (1) WO2002038609A2 (no)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
AU2002232642B2 (en) * 2000-12-12 2007-02-01 Lexicon Pharmaceuticals, Inc. Novel human kinases and uses thereof
AU2002249893B2 (en) 2001-01-02 2007-05-24 The Cleveland Clinic Foundation Myeloperoxidase, a risk indicator for cardiovascular disease
AU2002362612B2 (en) * 2001-09-28 2007-11-15 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
WO2004069795A2 (en) * 2003-02-03 2004-08-19 Pfizer Products Inc. Diagnosis and treatment of chronic tissue damage
EP2314285B2 (en) 2003-02-14 2019-09-18 Children's Hospital & Research Center at Oakland Lipophilic drug delivery vehicle and methods of use thereof
KR20050120663A (ko) * 2003-03-24 2005-12-22 세쿠오이아 파마큐티컬스 인코오퍼레이티드 장기간 작용하는 생물학적 활동 컨쥬게이트들
KR20050114283A (ko) * 2003-04-22 2005-12-05 아바니르 파마슈티컬스 고콜레스테롤혈증을 치료하기 위한 역 콜레스테롤 수송의매개제
EP1618135B1 (en) 2003-04-23 2013-06-26 F.Hoffmann-La Roche Ag Cleavage of fusion proteins using granzyme b protease
US7459286B1 (en) * 2003-10-22 2008-12-02 The Cleveland Clinic Foundation Assessing the risk of a major adverse cardiac event in patients with chest pain
EP2306192B1 (en) 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Risk Markers For Cardiovascular Disease
US20050176623A1 (en) * 2004-02-11 2005-08-11 Neil Wagle Non-invasive treatment of disease using amphipathic compounds
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
JP2007531537A (ja) * 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7378396B2 (en) * 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
AU2006282722A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holdings S.A. Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US20080248565A1 (en) * 2007-03-01 2008-10-09 Invitrogen Corporation Isolated phospholipid-protein particles
US20070117179A1 (en) * 2005-09-27 2007-05-24 Invitrogen Corporation In vitro protein synthesis systems for membrane proteins that include adolipoproteins and phospholipid-adolipoprotein particles
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US20110201548A1 (en) * 2007-04-23 2011-08-18 Nihon Pharmaceutical Co., Ltd. Therapeutic agent for acute hepatitis or prophylactic/therapeutic agent for fulminant hepatitis
WO2009048961A1 (en) * 2007-10-08 2009-04-16 Anaphore, Inc. Trimeric il-1ra
WO2009097587A2 (en) * 2008-01-30 2009-08-06 The Rockefeller University Nanoscale bound bilayers, methods of use and production
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
US8734853B2 (en) * 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
US20120157380A1 (en) * 2009-06-05 2012-06-21 Nan Wang Pegylated human apoa-1 and process for production thereof
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
AU2010329805B2 (en) * 2009-12-11 2016-07-14 Proyecto De Biomedicina Cima S.L. New conjugates and compositions for immunotherapy and anti-tumoral treatment
JP2013531990A (ja) * 2010-06-15 2013-08-15 シー． ローヤー，マシュー アテローム性動脈硬化症治療のための組成物および方法
CN101923093B (zh) * 2010-07-13 2013-12-18 昆明理工大学 树鼩IgG的三抗体夹心ELISA检测方法
EP2611419A2 (en) * 2010-08-30 2013-07-10 F.Hoffmann-La Roche Ag Method for producing a tetranectin-apolipoprotein a-1 lipid particle, the lipid particle itself and its use
BR112013004396A2 (pt) * 2010-08-30 2016-05-17 Hoffmann La Roche alimentação alcalina
CN103068369A (zh) * 2010-08-30 2013-04-24 霍夫曼-拉罗奇有限公司 产生四连蛋白-载脂蛋白a-i颗粒的方法，由此获得的脂质颗粒及其应用
EP2611921A2 (en) * 2010-08-30 2013-07-10 F.Hoffmann-La Roche Ag Prokaryotic expression construct
US20120190609A1 (en) * 2010-08-30 2012-07-26 Martin Bader Method for producing a lipid particle, the lipid particle itself and its use
MX2013002145A (es) 2010-08-30 2013-04-03 Hoffmann La Roche Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma.
EP2673296B1 (en) * 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
BR112013033562A2 (pt) 2011-08-25 2017-02-14 Hoffmann La Roche proteína de fusão de tetranectina-apolipoproteína a-i encurtada, uma partícula de lipídio que a contém e uso das mesmas
CN103703015B (zh) * 2011-08-25 2019-07-05 霍夫曼-拉罗奇有限公司 阳离子和阴离子交换层析法
PL2793913T3 (pl) * 2011-12-21 2023-11-06 Csl Limited Schemat dawkowania dla formulacji apolipoproteiny
WO2013125769A1 (ko) * 2012-02-24 2013-08-29 성균관대학교 산학협력단 아포리포단백질을 포함하는 항체-약물 결합체
KR101536037B1 (ko) * 2012-02-24 2015-07-13 성균관대학교산학협력단 아포리포단백질을 포함하는 항체-약물 결합체
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
WO2014023315A1 (en) * 2012-08-10 2014-02-13 Aarhus Universitet Multimerization through beta-strand swapping in ccp domains
EA033788B1 (ru) 2012-11-20 2019-11-26 Opko Biologics Ltd Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
EP3004160B1 (en) * 2013-06-05 2022-12-28 CSL Limited Process for preparing apolipoprotein a-i (apo a-i)
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
US10961286B2 (en) 2014-08-15 2021-03-30 Cornell University Nucleic acids, vectors, host cells, and methods for recombinantly producing water-soluble membrane proteins
HRP20230405T8 (hr) 2014-12-10 2023-09-29 Opko Biologics Ltd. Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta
ES2893616T3 (es) 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos
WO2017044424A1 (en) 2015-09-08 2017-03-16 Theripion, Inc. Apoa-1 fusion polypeptides and related compositions and methods
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
WO2018136163A2 (en) * 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
CA3074593A1 (en) * 2017-09-08 2019-03-14 The University Of Bristol Protein delivery to membranes
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
MX2023003877A (es) 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
KR20240018430A (ko) 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
CN114940711B (zh) * 2021-10-25 2023-05-12 中山大学 载脂蛋白a-i模拟肽及其应用
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3247588A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
CN115290776A (zh) * 2022-07-26 2022-11-04 云南大学 瘤牛锥虫病抗性蛋白的应用
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025175130A1 (en) * 2024-02-16 2025-08-21 The Children's Medical Center Corporation Apom fusion constructs and methods of use in treating inflammatory diseases
CN119823289B (zh) * 2025-03-20 2025-06-10 内蒙古和讯生物科技有限公司 一种蛋白基生物材料及其制备方法与应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) * 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5068045A (en) * 1985-08-27 1991-11-26 Mobil Oil Corporation Grease composition containing alkoxylated amide borates
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
US5128318A (en) * 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
IT1229996B (it) 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
US5182364A (en) * 1990-02-26 1993-01-26 The Scripps Research Institute Polypeptide analogs of apolipoprotein E
US5177189A (en) * 1989-08-18 1993-01-05 The Scripps Research Institute Polypeptide analogs of Apolipoprotein E
US5473039A (en) * 1989-08-18 1995-12-05 The Scripps Research Institute Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
AU9088891A (en) * 1990-11-29 1992-06-25 John E. Carbaugh Diagnostic and therapeutic compositions and methods for lipoprotein(a)
WO1993000077A1 (en) 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
WO1993000443A1 (en) * 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
US5408038A (en) * 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
WO1994004563A1 (fr) * 1992-08-14 1994-03-03 Shino-Test Corporation PEPTIDES CONTENANT DES SEQUENCES D'ACIDES AMINES RESPECTIVES SELECTIONNEES PARMI CELLES DE LA LIPOPROTEINE(a) ET DE L'APOLIPOPROTEINE(a), ANTICORPS RECONNAISSANT CES SEQUENCES D'ACIDES AMINES ET PROCEDE D'ANALYSE UTILISANT CES ANTICORPS
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
ATE143803T1 (de) 1992-12-22 1996-10-15 Univ Cincinnati Orale verabreichung von immunologischen aktiven biomolekülen und anderen therapeutischen proteinen
CA2155335C (en) 1993-02-04 2001-06-05 HANS CHRISTIAN THõGERSEN Improved method for the refolding of proteins
SE9300937L (sv) 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
US5643757A (en) 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
CA2230492C (en) * 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
AU736707B2 (en) 1997-06-11 2001-08-02 Anaphore, Inc. Trimerising module
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体

Also Published As

Publication number Publication date
EP1335938B1 (en) 2010-09-22
CY1111118T1 (el) 2015-06-11
JP2009118849A (ja) 2009-06-04
CA2428114C (en) 2013-07-23
JP2004522424A (ja) 2004-07-29
CA2428114A1 (en) 2002-05-16
US20090136467A1 (en) 2009-05-28
US20020156007A1 (en) 2002-10-24
EP2343317A1 (en) 2011-07-13
CN1268641C (zh) 2006-08-09
BR0115257A (pt) 2003-08-12
WO2002038609A2 (en) 2002-05-16
AU1384302A (en) 2002-05-21
WO2002038609A3 (en) 2002-09-26
AU2002213843A2 (en) 2002-05-21
NO20032101L (no) 2003-07-08
JP4344136B2 (ja) 2009-10-14
CN1486327A (zh) 2004-03-31
EP1335938A2 (en) 2003-08-20
US6897039B2 (en) 2005-05-24
NO331274B1 (no) 2011-11-14
US20050142639A1 (en) 2005-06-30
AU2002213843B2 (en) 2008-02-07
US20050096277A1 (en) 2005-05-05

Similar Documents

Publication Publication Date Title
NO20032101D0 (no) Apoliprotein analoger
DK1307486T3 (da) Somatostatinanaloger
DE60133511D1 (de) Fluorierte Ionomere
EP1353683A4 (en) ANALOGS BY GHRELIN
DK1250321T3 (da) Glyburidsammensætning
DE50114386D1 (de) Ng
FI20002644L (fi) Liitäntäalusta
DE60107598D1 (de) Smart-skin strukturen
DK1235777T3 (da) Vitamin D-analoger
DE60137169D1 (de) Entwicklungsgerät
NO20023246D0 (no) Hårstylingsfremgangsmåte
DK1235824T3 (da) D-vitaminanaloge forbindelser
DE60103292D1 (de) Fungizide zusammensetzungen
AR027931A1 (es) Antitranspirantes
DE60104126D1 (de) Fungizide formulierung
ATE268116T1 (de) Mesotrion-formulierungen
AR027982A1 (es) Aril- y heteroarilsulfonatos
ATA7092001A (de) Skibindungseinstellgerät
FI20002120A0 (fi) Sammutin
AT500246B8 (de) Chokerring
FR2817889B1 (fr) Coffrage
ATA17542000A (de) Hydraulikzylinder
ATA21172000A (de) Hackbrett
ATA19392000A (de) Kippflügelflugzeug
ATA12252000A (de) Regensinkkasten

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees